RT Journal Article
SR Electronic
T1 Evaluation of cancer-associated thrombosis risk in patients with lung adenocarcinoma using the COMPASS-CAT risk assessment model
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3854
DO 10.1183/13993003.congress-2021.PA3854
VO 58
IS suppl 65
A1 Miltiadis Chrysanthidis
A1 Andriani Charpidou
A1 Evangelos Dimakakos
A1 Dimitra Grapsa
A1 Petros Bakakos
A1 Grigorios Stratakos
A1 Konstantinos Syrigos
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA3854.abstract
AB Introduction: A variety of risk assessment models (RAMs) are being developed for the early identification of lung cancer patients at increased risk for Cancer-Associated Thrombosis (CAT).Aim: We herein aimed to evaluate the discrimination capacity of COMPASS-CAT RAM for the prediction of venous thromboembolism (VTE) risk in lung adenocarcinoma.Methods: The medical records of 129 patients with lung adenocarcinoma, diagnosed and treated at the Oncology Unit of “Sotiria” Athens General Hospital between June 2014 and May 2016, were retrospectively reviewed. VTE events were recorded and diagnostic accuracy measures of COMPASS-CAT RAM were calculated. The discrimination capacity of the model was tested with receiver operating characteristics (ROC) analysis.Results: The majority of patients were male (75%), with stage IV disease (69%). Incidence of CAT was 10.08%. Based on COMPASS-CAT score values, 62% of patients were stratified in the low/ intermediate CAT risk group and had CAT rate of 8.75%, while the remaining 38% were patients with high CAT risk and CAT rate of 12.24%. Sensitivity, specificity, positive predictive value and negative predictive value of COMPASS-CAT RAM were 46.15%, 62,93%, 12.24% and 91.25%, respectively, and the area under the curve (AUC) of ROC analysis was 0.611.Conclusions: COMPASS-CAT Score showed moderate discrimination and predictive capacity in our patient population. Further validation studies may be warranted prior to implementation of COMPASS-CAT RAM into routine clinical practice for patients with lung adenocarcinoma.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3854.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).